Olaparib

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Retrieved on: 
Saturday, October 21, 2023

Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Key Points: 
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated hypophysitis occurred in 1.3% (8/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.5%) adverse reactions.
  • Real-World Outcomes in Patients with Advanced Endometrial Cancer: A Retrospective Cohort Study of US Electronic Health Records.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, May 9, 2023

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023.
  • First Quarter 2023 Financial Overview:
    Balance Sheet: Cash, cash equivalents, and marketable securities were approximately $51.5 million as of March 31, 2023, compared to approximately $55.2 million as of December 31, 2022.
  • G&A Expenses: General and administrative expenses were approximately $1.7 million for the quarter ended March 31, 2023, compared to approximately $1.4 million for the quarter ended March 31, 2022.
  • Earnings Call and Webinar Details:
    Lantern will host its first quarter 2023 earnings call and webinar today, Tuesday, May 9, 2023 at 4:30 p.m.

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Retrieved on: 
Monday, April 17, 2023

BERWYN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for the patients that receive them, today announced that positive data from the Company’s tumor cell selective and broadly active small molecule with a unique mechanism of action, GP-2250 (misetionamide), was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

Key Points: 
  • “The data generated by GP-2250 to date has continued to demonstrate promising treatment potential for cancers.
  • These findings are encouraging and provide valuable insight as we advance the development of GP-2250 for the treatment of ovarian cancer.
  • With this growing body of data, we look forward to further evaluating GP-2250’s potential in the treatment of ovarian cancer,” commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • Dr. Sood commented, “There remains a significant unmet need in treatment options for ovarian cancer.

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

Retrieved on: 
Thursday, March 9, 2023

LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.

Key Points: 
  • LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.
  • The observations from these studies are further supported by in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern’s AI platform, RADR®.
  • “The combined anti-tumor potency of LP-100 in combination with PARP inhibitors, strongly supports the pursuit of this development pathway for LP-100,” stated Panna Sharma, Lantern’s President and CEO.
  • Lantern believes the simultaneous exploitation of both these mechanisms will enhance the development opportunities for LP-100, while also expanding potential market opportunities for existing PARP inhibitors.

LYNPARZA Market Drug Insight and Market Forecast 2023 - 2032: Detailed Descriptions of Mechanism of Action, Dosage and Administration and R&D Progress - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023

The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • "LYNPARZA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LYNPARZA for Pancreatic Cancer in the seven major markets.
  • In the DDR pathways, LYNPARZA is being tested in a range of PARP-dependent tumor types with defects and dependencies.
  • The report provides insights into:
    A comprehensive product overview including the LYNPARZA description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.

SeqOne’s New Clinically Validated HRD Test Reduces Number of Inconclusive Results to Improve the Prescription of Targeted Treatments for Ovarian Cancer Patients

Retrieved on: 
Wednesday, February 22, 2023

HRD status is key in the prescription of PARP inhibitor Olaparib, that improves survival of HRD positive patients.

Key Points: 
  • HRD status is key in the prescription of PARP inhibitor Olaparib, that improves survival of HRD positive patients.
  • SeqOne’s approach simplifies the deployment of this test so that it can be performed by any well equipped lab.
  • These results were clinically validated through a retrospective analysis of the PAOLA-1 cohort that was initially used to demonstrate the efficacy of Olaparib for HRD-positive patients.
  • In addition, SeqOne HRD has a smaller rate of inconclusive results compared to the inconclusive rate obtained with Myriad myChoice® CDx.

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

Retrieved on: 
Wednesday, January 4, 2023

Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with the European Network of Gynecological Oncology Trial Groups (“ENGOT”) and the GOG Foundation, Inc. (“GOG-F”) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.

Key Points: 
  • Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead
    Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of California San Diego, San Diego, CA) will be the co-GOG Foundation Trial Leads in the US
    Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with the European Network of Gynecological Oncology Trial Groups (“ENGOT”) and the GOG Foundation, Inc. (“GOG-F”) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.
  • “We are honored to collaborate with the ENGOT and GOG-F on this very important clinical trial.
  • ENGOT and GOG-F are the world's premier gynecology oncology clinical trials consortia, representing some of the leading medical centers and having spear-headed several drug approvals in the field, including the 2 PARP inhibitors for the treatment of BRCA-mutated ovarian cancers, Olaparib (Astra Zeneca) and Niraparib (GSK), as well as the antibody-drug conjugate Tivdak (Seattle Genetics), which is approved for cervical cancer,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
  • Clinical data from the ongoing Phase 1a trial to date suggest that the emerging clinical profile of NXP800 can provide a good balance between systemic exposure, pharmacodynamic activity and tolerability, and we look forward to the initiation of the Phase 1b trial in the next few months.”